

Amendments to the Claims:

Claims 1-21 (Cancelled).

Claim 22 (New): A method for treatment of diabetes mellitus and conditions associated with diabetes mellitus in a mammal, which method comprises administering 2 to 8 mg per day of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form, and an effective, non-toxic and pharmaceutically acceptable amount of glimepiride, to a mammal in need thereof.

Claim 23 (New): A method according to claim 22, which comprises administering 2 mg per day of said 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form.

Claim 24 (New): A method according to claim 22, which comprises administering 4 mg per day of said 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form.

Claim 25 (New): A method according to claim 22, which comprises administering 8 mg per day of said 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form.

Claim 26 (New): A method according to claim 22, which comprises administering a unit dosage form of said 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form, from 1 to 2 times per day.

Claim 27 (New): A method according to claim 22, which comprises administering a unit dosage form comprising 1, 2, 3, 4, 5, 6, 7 or 8 mg of said 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form, from 1 to 2 times per day.

Claim 28 (New): A method according to claim 27, comprising administering a unit dosage form comprising 1 mg of said 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form.

Claim 29 (New): A method according to claim 27, comprising administering a unit dosage form comprising 2 mg of said 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form.

Claim 30 (New): A method according to claim 27, comprising administering a unit dosage form comprising 4 mg of said 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form.

Claim 31 (New): A method according to claim 27, comprising administering a unit dosage form comprising 8 mg of said 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form.

Claim 32 (New): A method according to claim 27, comprising administering a unit dosage form comprising 2 mg of said 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form, twice per day.

Claim 33 (New): A method according to claim 27, comprising administering a unit dosage form comprising 4 mg of said 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form, twice per day.

Claim 34 (New): A method according to claim 27, wherein said unit dosage form is a tablet or a capsule.

Claim 35 (New): A method according to claim 22, which comprises co-administering said 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form, and glimepiride.

Claim 36 (New): A method according to claim 35, which comprises administering a formulation which comprises both of said 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form, and glimepiride.

Claim 37 (New): A method according to claim 35, which comprises administration of separate formulations of each of said 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form, and glimepiride.

Claim 38 (New): A method according to claim 22, which comprises sequential administration of said 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form, and glimepiride.

Claim 39 (New): A method according to claim 22, wherein said pharmaceutically acceptable form is a pharmaceutically acceptable salt form.

Claim 40 (New): A method according to claim 39, wherein said pharmaceutically acceptable salt is a maleate salt.

Claim 41 (New): A method according to claim 22, wherein said pharmaceutically acceptable form is a pharmaceutically acceptable solvate form.

Claim 42 (New): A method according to claim 22, wherein said pharmaceutically acceptable form is a pharmaceutically acceptable solvate of a pharmaceutically acceptable salt form.

Claim 43 (New): A method according to claim 41, wherein said pharmaceutically acceptable solvate is a hydrate.

Claim 44 (New): A method according to claim 42, wherein said pharmaceutically acceptable solvate is a hydrate.

Claim 45 (New): A method according to claim 22, which comprises administering a tablet or a capsule comprising 1 to 8 mg of said 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form, and glimepiride.

Claim 46 (New): A method according to claim 22, which comprises administering a tablet or a capsule comprising a pharmaceutically acceptable salt of said 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, and glimepiride.

Claim 47 (New): A method according to claim 22, which comprises administering a tablet or a capsule comprising 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione maleate, or a tautomer thereof, in a pharmaceutically acceptable form, and glimepiride.

Claim 48 (New): A method for treatment of Type II diabetes mellitus in a mammal, which method comprises administering 2 to 8 mg per day of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form, and an effective, non-toxic and pharmaceutically acceptable amount of glimepiride, to a mammal in need thereof.

Claim 49 (New): A pharmaceutical composition comprising 1 mg of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form, an effective, non-toxic and pharmaceutically acceptable amount of glimepiride, and a pharmaceutically acceptable carrier therefor.

Claim 50 (New): A pharmaceutical composition comprising 2 mg of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form, an effective, non-toxic and pharmaceutically acceptable amount of glimepiride, and a pharmaceutically acceptable carrier therefor.

Claim 51 (New): A pharmaceutical composition comprising 4 mg of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form, an effective, non-toxic and pharmaceutically acceptable amount of glimepiride, and a pharmaceutically acceptable carrier therefor.

Claim 52 (New): A pharmaceutical composition comprising 8 mg of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form, an effective, non-toxic and pharmaceutically acceptable amount of glimepiride, and a pharmaceutically acceptable carrier therefor.

Claim 53 (New): A pharmaceutical composition according to any one of claims 49-52, wherein said pharmaceutically acceptable form is a pharmaceutically acceptable salt form.

Claim 54 (New): A pharmaceutical composition according to claim 54, wherein said pharmaceutically acceptable salt is a maleate salt.

Claim 55 (New): A pharmaceutical composition according to any one of claims 49-52, wherein said pharmaceutically acceptable form is a pharmaceutically acceptable solvate form.

Claim 56 (New): A pharmaceutical composition according to any one of claims 49-52, wherein said pharmaceutically acceptable form is a pharmaceutically acceptable solvate of a pharmaceutically acceptable salt form.

Claim 57 (New): A pharmaceutical composition according to claim 55, wherein said pharmaceutically acceptable solvate is a hydrate.

Pred. Application No.: 10/103,326
Pred. Filing Date: March 21, 2002

Claim 58 (New): A pharmaceutical composition according to claim 56, wherein said pharmaceutically acceptable solvate is a hydrate.

Claim 59 (New): A method according to claim 22, wherein said 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form, is administered in a pharmaceutically acceptable composition comprising sodium starch glycollate, hydroxypropyl methylcellulose, microcrystalline cellulose and lactose monohydrate.